Erythropoietin receptor peptide formulations and uses

• US 7,919,461 B2
• Filed: 07/13/2007
• Issued: 04/05/2011
• Est. Priority Date: 06/03/2005
• Status: Expired due to Fees

• Current Assignee: Affymax Incorporated
• Original Assignee: Affymax Incorporated
• Inventors: Woodburn, Kathryn Wynne, Duliege, Anne-Marie, Stead, Richard, Leuther, Kerstin, Naso, Robert Barnett
• Primary Examiner(s): Russel; Jeffrey E
• Application Number:
  US11/777,500
• Publication Number:
  US 20080081783A1
• Time in Patent Office: 1,362 Days
• Field of Search: None
• US Class Current: 514/1.1
• CPC Class Codes: A61K 38/16 Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof enzyme inhibitors A61K38/005
• CPC Class Codes: A61K 38/1816 Erythropoietin [EPO]
• CPC Class Codes: A61K 47/60 the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
• CPC Class Codes: A61K 47/665 the pre-targeting system, clearing therapy or rescue therapy involving biotin-(strept) avidin systems
• CPC Class Codes: A61K 51/02 characterised by the carrier , i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
• CPC Class Codes: A61P 7/00 Drugs for disorders of the blood or the extracellular fluid
• CPC Class Codes: A61P 7/06 Antianaemics
• CPC Class Codes: B82Y 5/00 Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
• CPC Class Codes: C07K 14/505 Erythropoietin [EPO]

Abstract

The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, and dosages are also provided.

Claims

1. A method for treating a patient having chronic kidney disease (CKD), which method comprises administering once every 3 to 6 weeks to the patient a therapeutically effective amount of a compound according to Formula I that binds to and activates the erythropoietin receptor (EPO-R), wherein the therapeutically effective amount is a dosage of 0.25 to 1.25 milligram of the compound per 1 kilogram of body weight of the patient

2. The method according to claim 1 wherein the compound is Formula Ia

3. The method of claim 1, wherein the compound is administered in a composition comprising a pharmaceutically acceptable carrier.

4. The method of claim 1, wherein the therapeutically effective amount is administered once every 3 to 4 weeks.

5. The method of claim 1, wherein the dosage is 0.5 to 0.75 milligram of the compound per 1 kilogram of body weight of the patient.

6. The method of claim 1, wherein the therapeutically effective amount is administered once every 4 weeks.

7. The method of claim 1, wherein the therapeutically effective amount is administered by either intravenous or subcutaneous injection.

8. The method of claim 7, wherein the therapeutically effective amount is administered by subcutaneous injection.